[Treatment of infectious diseases due to methicillin-resistant Staphylococcus aureus (MRSA)].
Kanno
H
H
Clinical Laboratory Medicine, Chiba University Hospital.
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003428:Cross Infection / Q000517:prevention & control*; D004202:Disinfectants; D006801:Humans; D007769:Lactams; D018942:Macrolides; D016106:Methicillin Resistance; D011183:Postoperative Complications / Q000517:prevention & control; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000187:drug effects*; D013754:Tetracyclines / Q000494:pharmacology / Q000627:therapeutic use; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D004202:Disinfectants; D007769:Lactams; D018942:Macrolides; D015363:Quinolones; D013754:Tetracyclines; D014640:Vancomycin; D012293:Rifampin